Zafgen, Inc. (ZFGN) Receives Average Rating of “Hold” from Analysts

Shares of Zafgen, Inc. (NASDAQ:ZFGN) have received an average recommendation of “Hold” from the five ratings firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and two have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $6.63.

A number of equities analysts recently weighed in on ZFGN shares. Zacks Investment Research upgraded shares of Zafgen from a “hold” rating to a “buy” rating and set a $4.25 price target on the stock in a research report on Saturday, November 11th. ValuEngine upgraded shares of Zafgen from a “strong sell” rating to a “sell” rating in a report on Monday, October 16th.

In related news, Director Frances K. Heller purchased 10,000 shares of Zafgen stock in a transaction dated Friday, October 13th. The shares were acquired at an average cost of $3.90 per share, with a total value of $39,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 21.20% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. 683 Capital Management LLC grew its holdings in Zafgen by 8.5% during the 3rd quarter. 683 Capital Management LLC now owns 1,300,000 shares of the biopharmaceutical company’s stock worth $4,576,000 after acquiring an additional 101,600 shares in the last quarter. Vanguard Group Inc. grew its holdings in Zafgen by 15.7% during the 2nd quarter. Vanguard Group Inc. now owns 883,838 shares of the biopharmaceutical company’s stock worth $3,102,000 after acquiring an additional 119,902 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Zafgen by 31.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 584,159 shares of the biopharmaceutical company’s stock worth $2,050,000 after acquiring an additional 140,848 shares in the last quarter. Mangrove Partners acquired a new position in Zafgen during the 3rd quarter worth approximately $1,971,000. Finally, Goldman Sachs Group Inc. grew its holdings in Zafgen by 1,701.5% during the 2nd quarter. Goldman Sachs Group Inc. now owns 197,287 shares of the biopharmaceutical company’s stock worth $692,000 after acquiring an additional 186,336 shares in the last quarter. 48.70% of the stock is currently owned by hedge funds and other institutional investors.

Zafgen (ZFGN) traded up $0.07 on Friday, reaching $3.77. 44,282 shares of the company were exchanged, compared to its average volume of 193,620. Zafgen has a 52-week low of $3.15 and a 52-week high of $5.46.

Zafgen (NASDAQ:ZFGN) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.12. analysts anticipate that Zafgen will post -2.02 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Zafgen, Inc. (ZFGN) Receives Average Rating of “Hold” from Analysts” was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://sportsperspectives.com/2017/12/15/zafgen-inc-zfgn-receives-average-rating-of-hold-from-analysts.html.

Zafgen Company Profile

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply